CureDuchenne and REGENXBIO Webinar: RGX-202 - REGENXBIO’s investigational gene therapy for DMD

Описание к видео CureDuchenne and REGENXBIO Webinar: RGX-202 - REGENXBIO’s investigational gene therapy for DMD

Join REGENXBIO’s Senior Director and Clinical Development Lead, Dr. Jahannaz Dastgir and Dr. Veerapandiyan from Arkansas Children’s Hospital to receive updates about RGX-202, an investigational gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne) and trials: the AFFINITY DUCHENNE™ Phase I/II trial of RGX-202 and AFFINITY BEYOND™, an antibody assessment study in boys with Duchenne.

Комментарии

Информация по комментариям в разработке